- Home
- CISS vs MYNZ Comparison
CISS vs MYNZ Comparison
Compare CISS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | MYNZ |
|---|---|---|
| Founded | 2022 | 2021 |
| Country | Greece | Germany |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 8.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CISS | MYNZ |
|---|---|---|
| Price | $0.21 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.5M | 252.9K |
| Earning Date | 11-18-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,613,149.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | $0.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $0.92 |
| 52 Week High | $11.52 | $8.20 |
Technical Indicators
Market Signals| Indicator | CISS | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 16.29 | 44.25 |
| Support Level | $0.20 | $1.00 |
| Resistance Level | $0.28 | $1.15 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 0.80 | 46.29 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.